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Abstract
Background
Cough is one of the most common symptoms in general and pulmonary medicine with pro-
found negative impact on health-related quality of life (HRQL). The Leicester Cough Ques-
tionnaire (LCQ) is a validated HRQL questionnaire, yet a validated German version of the
LCQ is not available and it has never been tested in a cohort with sarcoidosis.
Objectives
To translate the LCQ into German and determine its psychometric properties.
Methods
The LCQ was translated in a forward-backward approach. Structured interviews in sarcoido-
sis patients were performed. Subsequently, sarcoidosis patients were asked to answer
the German LCQ and comparative questionnaires. Distribution properties, item difficulty,
concurrent validity, Rasch model fit and internal consistency of the German LCQ were
determined.
Results
200 patients with sarcoidosis were included. We provide evidence for reliability, unidimen-
sionality and internal consistency. However, only a moderate correlation with general and
respiratory-specific HRQL questionnaires, no Rasch model fit could be shown. Skewed
responses caused by floor effects were detected.
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Conclusion
We demonstrate that the German LCQ is valid and reliable and its psychometric properties
fulfil the standards required for its use in clinical settings as well as in interventional trials.
Introduction
Cough is one of the most common symptoms in general and pulmonary medicine and has a
profound negative impact on health-related quality of life (HRQL) in affected patients[1].
Patients with chronic cough suffer from physical illness, like chest pain, syncope and inconti-
nence, and psychological morbidity, like social embarrassment and depression[2]. A myriad of
diseases can cause chronic cough, common diseases like asthma or gastroesophageal reflux dis-
ease or rare diseases like sarcoidosis.
Sarcoidosis is a systemic granulomatous disease of unknown aetiology[3]. Patients with sar-
coidosis typically suffer from pulmonary symptoms like cough, dyspnoea or chest pain with
subsequent reduction of their general health status and their respiratory-specific HRQL[3–6].
Cough is a common symptom in patients with sarcoidosis, with up to 50% affected patients
[6–8]. Bronchial involvement, which can be demonstrated histologically, is supposed to be
causative for cough in sarcoidosis patients[9]. In sarcoidosis, endpoints of clinical studies differ
either depending on organ involvements or on general sarcoidosis symptoms like fatigue[10].
As symptoms like cough are difficult to be quantified objectively and usually accompanied
with psychological morbidity, patient-reported outcomes should be implemented, at least as
secondary endpoint, in clinical trials. The inclusion of measurements of HRQL in clinical trials
is thus recommended by the World Association of Sarcoidosis and Other Granulomatous dis-
ease (WASOG)[10].
The Leicester Cough Questionnaire (LCQ) is a validated HRQL questionnaire on cough
with three domains covering physical, psychological and social aspect of chronic cough[11].
The minimal important difference of the LCQ has already been established[12]. The LCQ has
been translated into several languages including Dutch, Korean, Lithuanian, Mandarin, Polish,
Portuguese and Spanish, and validated in corresponding cohorts[13–22]. It has been validated
in different diseases, like chronic cough itself, cystic fibrosis including in children, bronchiec-
tasis and COPD, yet not in a sarcoidosis cohort[20,23–25]. Furthermore, a revised version, the
LCQ-acute, was developed for patients with acute cough[26].
The LCQ was already applied in several clinical studies on chronic cough testing
different drugs including azithromycin, esomeprazole and itraconazole[27–29], as well as
in a positive clinical study proving that morphine is an effective antitussive in chronic
cough[30]. At the moment, it is in use in several clinical trials like in azithromycin in
chronic productive cough (ClinicalTrials.gov Identifier: NCT02196493), amikacin in acute
exacerbation of bronchiectasis (NCT02509091) or dornase alpha after lung transplantation
(NCT01952470).
Taken together, the LCQ has been translated in multiple languages and validated in several
diseases and is utilized in several completed and ongoing clinical studies, yet a validated Ger-
man version of the LCQ is not available and it has never been tested in a cohort with sarcoido-
sis. Therefore, we aimed to translate and validate a German version of the LCQ in sarcoidosis
patients to provide an instrument for future multinational observational and interventional
studies on chronic cough and in particular in sarcoidosis.
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Methods
Translation
In order to translate the LCQ[11] into German and validate it in a German cohort a multistep
forward-backward approach was chosen[31]: First, the English version of the LCQ was inde-
pendently translated by five authors (EFG, JMQ, JCS, WW, CPC), merged to a preliminary
version followed by a backward translation by a native speaker. Some suggestions of the origi-
nal author (SSB) were implemented, and afterwards the conceptual and cultural equivalence
was confirmed by him. This German pilot version was tested in structured interviews of ten
patients with sarcoidosis. Minor, final modifications based on these structured interviews were
implemented and documented.
Subjects
200 consecutive sarcoidosis patients of at least 18 years of age diagnosed of sarcoidosis according
to the consensus statement of three scientific societies (ERS, ATS, WASOG)[32] were recruited
over 12 months in the outpatient clinic of the department of pneumology of the university medi-
cal centre Freiburg. We obtained a positive vote by the Ethics Committee of the Albert Ludwig
University of Freiburg, Freiburg, Germany prior to the initiation of the study and it was regis-
tered in the German Clinical Trials Register (reference number DRKS00010072).
Study procedure
The participants were asked the following questionnaires and measurements: the LCQ in Ger-
man, the Short Form (36) Health Survey (SF-36)[33], the Borg dyspnoea scale (CR-10)[34]
and the visual analogue scale for dyspnoea (VAS-D)[35]. Furthermore, patients answered
structured questions on their nationality, sex, duration of the disease, days of sickness per year,
highest educational certificate, employment and family status.
Statistical analysis
Our approach follows the original publication of the LCQ and another validation paper in the
Dutch context[11,24].
Distribution properties. To give descriptive information and distribution properties,
nonresponse rates, item difficulty, skewness and kurtosis were computed. Items with inappro-
priately high item difficulty, skewness or kurtosis as well as items with ceiling or floor effects
were determined. Regarding the classification of ceiling and floor effects, we follow the
approach of McHorney & Tarlov, Varni et al, and Lin et al defining a percentage of 0 to 15% as
small, 16% to 30% as moderate and more than 30% as substantial floor or ceiling effect [36–
38].
Item difficulty. In order to check for item difficulty, we computed the item difficulty
index [39] using the sum of squared item values divided by the sum of squared maximum val-
ues. The calculated index ranges from 0 to 1 and is sensitive to the variance of multiscale items.
Confirmatory factor analysis. We conducted a confirmatory factor analysis using IBM
SPSS AMOS 24 software to confirm the item-factor-relationship. A three-factor solution (cor-
responding to the assumed three constructs of the LCQ) was tested, based on a Maximum
Likelihood estimation. Model fit was evaluated using Chi2 goodness of fit test, the Comparative
Fit Index (CFI)[40], Tucker–Lewis index (TLI)[41], root mean square error of approximation
(RMSEA), and standardized root mean square residual (SRMR). A non-significant Chi2 test
indicates that the assumed model fits well the data. CFI and TLI values > 0.90 are considered
as indication of good fit. RMSEA values<0.10 suggest a moderate fit; values <0.05 are a good
Validation of the German LCQ in sarcoidosis
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fit[40]. The SRMR value should be under 0.08[40]. Satisfactory model fit is assumed whenever
at least three out of four parameters produce good values[42]. In order to improve model fit,
we additionally test a modified model. In order to do this, modification indices were explored
to suggest residual correlations entailing a substantial improvement of fit [43]. However, we
considered only changes if they were theoretically plausible.
Item response theory (IRT) analyses. We used the 1-parameter logistic IRT model
(Rasch model) for item response theory analyses (software: WINSTEPS version 3.68), as it is
an effective tool for clinical applications[44]. Following Reeve et al.[45], we chose a partial
credit model as it also provides stable parameter estimates for even small case numbers and
furthermore because the response categories are not identical for all items [45,46]. Infit and
outfit mean square residual statistics (Infit MNSQ, Outfit MNSQ) were used as goodness-of-
fit statistics. Mean squares greater than 1.0 indicate underfit to the Rasch model, meaning
that a part of the model’s variance lies outside the underlying factor concept. Mean squares
less than 1.0 indicate overfit to the Rasch model, meaning that the data is more predictable
than the model expects [47,48]. For survey rating scales a suitable item mean-square range
from 0.6 to 1.4 is recommended [47]. Items with a poor infit or outfit were discussed. Addi-
tionally, we checked for disordered response categories in the items by calculating the ability
means for each item in WINSTEPS [48]. Disorder might occur for example if respondents
find it difficult to differentiate between the various response categories for a particular item
[49].
Internal consistency. Cronbach’s Alpha was calculated. Values between 0.7 and 0.8 can
be considered as good, values between 0.90 and 0.95 as excellent. Values higher than 0.95 indi-
cate item redundancy [50,51]. Item-total correlation >0.4 indicates that the item is adherent to
other items measured using the same latent construct [52]. Concurrent validity: To evaluate
concurrent validity, we tested the hypotheses below:
1. As the Borg scale and the VAS Dyspnoea assess lung symptoms, we expect moderate (nega-
tive) correlations (0.30> = r>0.5) of these parameters with the LCQ scales.
2. We expect high correlations (r> = 0.60) between the LCQ subscale “Physical” and the SF-
36 Physical component scales, as well as between the LCQ subscales “Psychological” and
“Social” and the SF-36 Mental component scales.
Results
Structured interviews
A pilot German LCQ was field-tested in ten patients with sarcoidosis by structured interviews.
No patients had problems with understanding or answering the questionnaire. Some minor
modifications were made in the final German LCQ to improve the comprehensibility of the
questionnaire.
Patient characteristics
200 patients with sarcoidosis were included in this study. We identified 5 cases with complete
missing values on the 19 LCQ items and 2 cases with missing values on more than 50% of the
LCQ items. By removing those seven cases from the analysis we ended up with a sample size
of 193 patients. 48.7% of the patients were females, the mean age was 52.9 (± 12.6) years (see
Table 1). 33.9% of the patients were unemployed, and in 30.1% of the patients the educational
level corresponded to that of primary school. The majority of the patients (83.7%) suffered
from a chronic course of their disease with at least three years of illness duration.
Validation of the German LCQ in sarcoidosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0205308 October 4, 2018 4 / 11
Distribution properties
In sum, 172 patients (86%) completed all 19 LCQ items. Overall, all items show low non-
response rates with the highest rate (3.1%) on item number 9 (see S1 Table). All but one (item
15) items show floor effects with more than 30% of responses in the extreme categories indicat-
ing that the observed population is quite healthy. Both Skewness and Kurtosis lie in the range
of -1.95 to +1.95 for almost all items except for item number 12 and 17. In those two items, the
Kurtosis is slightly higher than the cut-off point.
Item difficulty
Item difficulty values are considered as good when they score between 0.2 and 0.8. Higher values
indicate that items are too easy and lower values indicate that items are too difficult. All index
values lie in this range except for items 12, 14 and 17, which have high values indicative for
being too easy (see S2 Table). The highest index value is reached for item number 12 with 0.83.
Item response theory (IRT) analyses
Items were tested for Rasch model fit. Infit and outfit values that were beyond acceptable cut-
offs were detected for items 3, 4, 5, 9, 11, 15 and 16. Inspection of the ability means for each
Table 1. Patient characteristics.
Variable Nmax = 193
Age M and SD 52.91 (12.62)
Sex N (%)
Female 93 (48.7)
Male 98 (51.3)
Nationality N (%)
German 172 (92.0)
Other 15(8.0)
Partnership N (%)
Yes 144 (79.6)
No 37 (20.4)
Level of education N (%)
Elementary school 56 (30.3)
Secondary school 63 (34.1)
Polytechnic secondary school 2 (1.1)
Technical college qualification 13 (7.0)
University qualification 44 (23.8)
Other or no certificate 7 (3.8)
Employment status N (%)
Employed 115 (66.1)
Unemployed 59 (33.9)
Duration of illness sarcoidosis N (%)
< 1 year 11 (6.2)
1–2 years 18 (10.1)
3–5 years 60 (33.7)
6–10 years 49 (27.5)
> 10 years 40 (22.5)
Notes: Totals not adding up to N = 193 are the result of missing values. M = mean score, SD = standard deviation.
The percentages refer to the raw values including missing values.
https://doi.org/10.1371/journal.pone.0205308.t001
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item demonstrate disordered response thresholds for items 1, 4, 9, 13, 14, 15, 17 and 18. Over-
all, the LCQ does not fit to the probabilistic distribution of item response theory.
Confirmatory factor analysis
Table 2 shows model fit statistics as a result of the confirmatory factor analysis. The original
model showed barely satisfactory fit (p<0.001, TLI = 0.88, CFI = 0.9, RMSEA = 0.11). As mod-
ification indices suggested that model fit would be improved if correlated error terms were
added, we identified three error term correlations we consider as reasonable. Two items refer
to insomnia (physical subscale) and general frustration (psychological subscale) which might
highly correlate and have a joint component not entirely explained by the underlying factors.
Two other items comprise both the term “sorrow” (psychological subscale) which might cause
high correlations. The last two items (Social subscale) we correlated refer to the impact of
cough on general life aspects. We modified the model accordingly so that the new model
shows improved model fit with a decreased Chi2 value of 298.84 and satisfactory TLI and CFI
values above 0.9. RMSEA decreased to 0.10. The Chi2 test still suggests no good model fit.
However, Chi2 tests have been found to be too sensitive to large sample sizes [37,53,54]. There-
fore, we rely more to the other applied model fit indices and consider the modified model as
satisfactory.
Internal consistency
Indicators for internal consistency are represented in Table 3. Cronbach’s Alpha is good to
excellent for all three subscales of the LCQ (Cronbach’s alpha ranging from 0.87 to 0.94). The
Item-total correlation falls below the acceptable range for the subscale “Physical” (0.24 to 0.74).
We found that Cronbach’s Alpha of 0.87 would not decrease if item 15 would be eliminated.
However, the mean inter-item correlation coefficient values do not fall below 0.44 so that we
conclude that no items should be eliminated. Nevertheless, it should be mentioned that the
subscale “physical” was the one with the weakest performance regarding internal consistency.
Table 2. Global fit indices of confirmatory factor analysis.
N χ 2 df p χ 2/df TLI CFI RMSEA RMSEA 90% CI SRMR
Original CFA model a 172 477.94 149 < .001 3.21 0.88 0.90 0.11 0.10–0.13 0.04
Modified CFA model b 172 398.84 146 < .001 2.73 0.91 0.92 0.10 0.09–0.11 0.04
Notes:
a Though EFA-(PCA) analysis suggested a one-factor solution, we performed an original CFA with the three latent variables “psychological, physical, social”.
b As modification indices suggested that model fit would be improved if correlated error terms were included, we added three theoretically plausible correlated error
terms.
Abbreviations: CFI: comparative fit index, CI: confidence interval, df: degrees of freedom, RMSEA: root mean square error of approximation, SRMR: standardized root
mean square residual, TLI: Tucker–Lewis index.
https://doi.org/10.1371/journal.pone.0205308.t002
Table 3. Internal consistency.
Scale and items N Items Item-Total correlation Mean Inter-Item correlation Cronbach’s alpha
Physical
Includes items 01, 02, 03, 09, 10, 11, 14, 15
181 8 0.24–0.74 0.47 0.87
Psychosocial
Includes items 04, 05, 06, 12, 13, 16, 17
183 7 0.53–0.83 0.70 0.94
Social
Includes items 07, 08, 18, 19
187 4 0.66–0.90 0.73 0.92
https://doi.org/10.1371/journal.pone.0205308.t003
Validation of the German LCQ in sarcoidosis
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Concurrent validity
As expected in hypothesis 1, we observed moderate correlations with Borg scale and the VAS
Dyspnoea, with a Pearson’s r around -0.5 (details see Table 4). However, we detected signifi-
cant negative correlations with all LCQ subscales. Hypothesis 2 cannot be confirmed, since
the assumed correlations were only moderate. The correlations are significant and in the right
direction, but all of them are only moderate and do not reach a Pearson’s r of 0.6.
Discussion
In this study, we translated the LCQ into German language, and examined its psychometric
properties in a sarcoidosis cohort. We had sufficient information to analyse 193 out of 200
included patients, which is an acceptable rate for a validation study. In addition, the overall
response rates were high. Only item number 9 had a relatively higher non-response frequency,
which can be the result of the specific situation as the question asks for exposure to paints or
fumes. This situation does not apply for every patient. Furthermore, we observed floor effects
in most of the items which indicates that either the chosen reference time (2 weeks) might be
too short or the patients overall show no severe health problems. The lowest response category
however represents “Never/not at all” which cannot be differentiated any more.
The internal consistency of the German LCQ was good to excellent, with Cronbach’s
Alphas between 0.87 to 0.94 for the three subscales. The high internal consistency of the Ger-
man LCQ, as well as the moderate concurrent validity compared to general health or respira-
tory-specific HRQL questionnaires, is in line with published data, after translation into several
other languages[15,16,19,22,55] as well as in the original LCQ[11]. In this regard it is astonish-
ing that the Physical Component Summary Score (PCS) of the SF-36 showed a quite high cor-
relation with the LCQ, while the Mental Component Summary Score (MCS) does not. This
might indicate that the LCQ does measure HRQL aspects which are not covered by the SF-36
Table 4. Concurrent validity.
Leicester Cough Questionnaire
Physical Psychological Social
SF-36 Role-Physical index .424 .315 .374
SF-36 Physical Functioning index .579 .466 .507
SF-36 Bodily Pain index .429 .264 .288
SF-36 General Health Perceptions index .487 .412 .423
SF-36 Vitality index .475 .338 .352
SF-36 Social Functioning index .435 .375 .388
SF-36 Role-Emotional index .240 .220 .243
SF-36 Mental Health index .254 .172 .193
SF-36 Standardized Physical Health index .560 .403 .439
SF-36 Standardized Mental Health index .218 .198 .216
Borg scale -.538 -.520 -.554
VAS Dyspnoea -.572 -.533 -.529
Notes: Pearson’s correlations,
p<0.05,
p<0.01,
p<0.001. Interpretation guide: LCQ scales: high values = low burden, SF-36 scales: high values = high manifestation of related dimensions’ content, Borg scale: high
values = high dyspnoea, VAS Dyspnoea: high values = high dyspnoea.
https://doi.org/10.1371/journal.pone.0205308.t004
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emphasizing the importance not only to use the SF-36, but also the LCQ. Here, a moderate
correlation does not necessarily mean moderate validity.
The strengths of this study are the use of up-to-date patient reported outcome methodol-
ogy, including item response modelling and confirmatory factor analyses, and to reach such a
sample size in a specific patient group, which was sufficient for the statistical analyses con-
ducted. The main limitations of this study are floor effects mainly because sarcoidosis patients
were included regardless of the presence of cough. The moderate concurrent validity and miss-
ing Rasch model fit might therefore be attributable to our cohort and might improve if the
German LCQ would be applied in a cohort suffering from more severe cough or higher cough
frequencies. Further limitations are the following: Patients answered the questionnaire only
once, so we cannot evaluate the test-retest-reliability. Additionally, CFA might have suffered
from a insufficient sample size [56]. A validation cohort is missing, especially to confirm the
good model fit in the CFA. Furthermore, we do not have objective data on physiological
parameters of cough, like cough frequency, spectra or duration, which might show improved
concurrent validity of the LCQ. And last, we only included patients with sarcoidosis which
limits the generalizability of our results for patients with cough as a symptom of other diseases
but demonstrates unequivocally its usefulness for measuring sarcoidosis associated cough.
In conclusion, we validated the German LCQ and could show that the psychometric prop-
erties of the German LCQ are acceptable for its general application and good for its use in
sarcoidosis studies. We provide evidence for reliability, unidimensionality and internal consis-
tency. However, some limitations might raise concerns. Only a moderate concurrent validity,
and no Rasch model fit were detected. Furthermore, we found strong floor effects that indicate
that the LCQ has limitations regarding its applicability in an asymptomatic sarcoidosis popula-
tion. However, the moderate concurrent validity is in agreement with the concurrent validity
in various other cohorts. Further testing is needed in order to confirm the discriminatory
power between the subscales “Physical”, “Psychological” and “Social”. Disregarding the prob-
lem of construct validity, we suggest further investigating external validity and possible scale
transformations in order to reach Rasch model fit. Further research with larger sample sizes is
needed to investigate test-retest reliability and Rasch model fit. The German LCQ is valid, reli-
able, and ready to use in clinical settings as well as in pharmacological trials.
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